Publicaciones en las que colabora con Jesús García-Donas Jiménez (13)

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

    Kidney Cancer, Vol. 6, Núm. 3, pp. 169-178

  3. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

  4. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy

    ESMO Open, Vol. 7, Núm. 2

2018

  1. A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma

    Clinical Cancer Research, Vol. 24, Núm. 10, pp. 2350-2356

2017

  1. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity

    Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16

  2. Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

    Pharmacogenetics and Genomics, Vol. 27, Núm. 6, pp. 227-231

  3. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  4. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

    Oncotarget, Vol. 8, Núm. 1, pp. 1204-1212

  5. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02

    Annals of Oncology, Vol. 27, pp. vi277

2015

  1. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma

    European Journal of Clinical Pharmacology, Vol. 71, Núm. 12, pp. 1477-1484

  2. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993